Viatris Gross Margin 2010-2024 | VTRS
Current and historical gross margin for Viatris (VTRS) over the last 10 years. The current gross profit margin for Viatris as of March 31, 2024 is %.
| Viatris Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2024-03-31 | $15.36B | $6.40B | 41.67% |
| 2023-12-31 | $15.43B | $6.44B | 41.74% |
| 2023-09-30 | $15.47B | $6.12B | 39.54% |
| 2023-06-30 | $15.60B | $6.17B | 39.57% |
| 2023-03-31 | $15.80B | $6.27B | 39.66% |
| 2022-12-31 | $16.26B | $6.50B | 39.94% |
| 2022-09-30 | $16.73B | $6.77B | 40.46% |
| 2022-06-30 | $17.19B | $6.59B | 38.36% |
| 2022-03-31 | $17.65B | $6.22B | 35.24% |
| 2021-12-31 | $17.89B | $5.58B | 31.17% |
| 2021-09-30 | $17.17B | $4.74B | 27.58% |
| 2021-06-30 | $15.60B | $4.32B | 27.69% |
| 2021-03-31 | $13.76B | $4.02B | 29.21% |
| 2020-12-31 | $11.95B | $3.80B | 31.78% |
| 2020-09-30 | $11.51B | $4.18B | 36.29% |
| 2020-06-30 | $11.50B | $4.09B | 35.56% |
| 2020-03-31 | $11.63B | $4.00B | 34.39% |
| 2019-12-31 | $11.50B | $3.90B | 33.88% |
| 2019-09-30 | $11.39B | $3.83B | 33.59% |
| 2019-06-30 | $11.29B | $3.79B | 33.60% |
| 2019-03-31 | $11.25B | $3.82B | 34.00% |
| 2018-12-31 | $11.43B | $4.00B | 35.00% |
| 2018-09-30 | $11.59B | $4.28B | 36.92% |
| 2018-06-30 | $11.72B | $4.42B | 37.72% |
| 2018-03-31 | $11.87B | $4.68B | 39.43% |
| 2017-12-31 | $11.91B | $4.78B | 40.17% |
| 2017-09-30 | $11.94B | $4.82B | 40.40% |
| 2017-06-30 | $12.01B | $4.93B | 41.04% |
| 2017-03-31 | $11.61B | $4.88B | 42.00% |
| 2016-12-31 | $11.08B | $4.70B | 42.40% |
| 2016-09-30 | $10.30B | $4.43B | 42.96% |
| 2016-06-30 | $9.94B | $4.46B | 44.85% |
| 2016-03-31 | $9.75B | $4.29B | 44.04% |
| 2015-12-31 | $9.43B | $4.22B | 44.71% |
| 2015-09-30 | $9.02B | $4.12B | 45.69% |
| 2015-06-30 | $8.41B | $3.82B | 45.40% |
| 2015-03-31 | $7.88B | $3.62B | 45.96% |
| 2014-12-31 | $7.72B | $3.53B | 45.70% |
| 2014-09-30 | $7.45B | $3.36B | 45.06% |
| 2014-06-30 | $7.13B | $3.15B | 44.21% |
| 2014-03-31 | $6.99B | $3.09B | 44.11% |
| 2013-12-31 | $6.91B | $3.04B | 44.01% |
| 2013-09-30 | $6.82B | $2.99B | 43.77% |
| 2013-06-30 | $6.86B | $2.97B | 43.32% |
| 2013-03-31 | $6.85B | $2.93B | 42.83% |
| 2012-12-31 | $6.80B | $2.91B | 42.78% |
| 2012-09-30 | $6.61B | $2.81B | 42.56% |
| 2012-06-30 | $6.38B | $2.68B | 41.95% |
| 2012-03-31 | $6.27B | $2.64B | 42.17% |
| 2011-12-31 | $6.13B | $2.56B | 41.81% |
| 2011-09-30 | $6.03B | $2.50B | 41.39% |
| 2011-06-30 | $5.81B | $2.42B | 41.62% |
| 2011-03-31 | $5.61B | $2.29B | 40.88% |
| 2010-12-31 | $5.45B | $2.22B | 40.68% |
| 2010-09-30 | $5.37B | $2.15B | 40.13% |
| 2010-06-30 | $5.28B | $2.08B | 39.40% |
| 2010-03-31 | $5.18B | $2.07B | 39.90% |
| 2009-12-31 | $5.09B | $2.08B | 40.74% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.478B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $124.523B | 15.62 |
| Cencora (COR) | United States | $45.467B | 17.73 |
| ICON (ICLR) | Ireland | $25.839B | 24.39 |
| DiDi Global (DIDIY) | China | $20.560B | 0.00 |
| Avantor (AVTR) | United States | $14.550B | 21.42 |
| CochLear (CHEOY) | Australia | $14.235B | 0.00 |
| Natera (NTRA) | United States | $13.510B | 0.00 |
| Medpace Holdings (MEDP) | United States | $13.148B | 43.26 |
| Revvity (RVTY) | United States | $13.044B | 22.88 |
| Charles River Laboratories (CRL) | United States | $10.681B | 20.45 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.978B | 0.00 |
| Solventum (SOLV) | United States | $8.865B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.503B | 0.00 |
| HealthEquity (HQY) | United States | $7.335B | 47.10 |
| Organon (OGN) | United States | $5.295B | 5.02 |
| Bausch + Lomb (BLCO) | Canada | $5.197B | 20.80 |
| Doximity (DOCS) | United States | $5.160B | 36.14 |
| PACS (PACS) | United States | $4.601B | 0.00 |
| Life Times (LTH) | United States | $3.772B | 39.52 |
| Sotera Health (SHC) | United States | $3.369B | 16.53 |
| Surgery Partners (SGRY) | United States | $3.091B | 28.28 |
| GoodRx Holdings (GDRX) | United States | $2.885B | 109.86 |
| Progyny (PGNY) | United States | $2.725B | 46.92 |
| Agilon Health (AGL) | United States | $2.710B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.968B | 7.80 |
| Premier (PINC) | United States | $1.926B | 8.24 |
| NovoCure (NVCR) | Jersey | $1.897B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.854B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.720B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.566B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.501B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.207B | 0.00 | |
| CareDx (CDNA) | United States | $0.749B | 0.00 |
| Embecta (EMBC) | United States | $0.719B | 4.89 |
| InnovAge Holding (INNV) | United States | $0.713B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.696B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.608B | 6.45 |
| Auna S.A (AUNA) | Luxembourg | $0.594B | 0.00 |
| Sharecare (SHCR) | United States | $0.500B | 0.00 |
| Enhabit (EHAB) | United States | $0.430B | 42.85 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.410B | 0.00 |
| ModivCare (MODV) | United States | $0.359B | 6.71 |
| QDM (QDMI) | Hong Kong, SAR China | $0.353B | 9.24 |
| Sonida Senior Living (SNDA) | United States | $0.348B | 0.00 |
| DocGo (DCGO) | United States | $0.326B | 17.83 |
| LifeMD (LFMD) | United States | $0.279B | 0.00 |
| MultiPlan (MPLN) | United States | $0.272B | 0.00 |
| Beauty Health (SKIN) | United States | $0.235B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.208B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.187B | 0.00 |
| Biodesix (BDSX) | United States | $0.172B | 0.00 |
| So-Young (SY) | China | $0.108B | 52.00 |
| Pono Capital Two (PTWO) | United States | $0.070B | 0.00 |
| NeueHealth (NEUE) | United States | $0.043B | 5.78 |
| Co-Diagnostics (CODX) | United States | $0.040B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.034B | 0.00 |
| Oncology Institute (TOI) | United States | $0.033B | 0.00 |
| Nutex Health (NUTX) | United States | $0.029B | 0.00 |
| OncoCyte (OCX) | United States | $0.024B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.023B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.021B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.021B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.019B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.017B | 0.00 |
| KindlyMD (KDLY) | $0.017B | 0.00 | |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| Assure Holdings (IONM) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.004B | 0.00 |
| OpGen (OPGN) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |